Table 1.
Demographic and clinical characteristics of the ten HIV-positive liver transplant recipients
| Patient | Sex | Age | Year of tx | Immunosuppressive therapy | ART early post-tx | ART maintenance post-tx | Post-tx follow-up |
|---|---|---|---|---|---|---|---|
| 1 | M | 63 | 2007 | Tacrolimus | TDF/FTC/uFPV | TAF/FTC/DTG | Increment of serum transaminases (+ 100–400%), variable tacrolimus concentrations, switched to TAF/FTC/uFPV |
| 2 | M | 57 | 2010 | Cyclosporine | ABC/3TC/RAL | ABC/3TC/DTG | DTG-based HAART maintained |
| 3 | M | 57 | 2010 | Tacrolimus/everolimus | TDF/FTC/RAL | TAF/FTC/DTG | DTG-based HAART maintained |
| 4 | M | 60 | 2011 | Cyclosporine | TDF/FTC/RAL | TAF/FTC/DTG | DTG-based HAART maintained |
| 5 | M | 52 | 2012 | Cyclosporine/everolimus | TDF/FTC/RAL | TAF/FTC/DTG | DTG-based HAART maintained |
| 6 | M | 58 | 2014 | Cyclosporine | ATV/r/RAL | ATVr/DTG | Increment of serum creatinine (+ 38%), some cyclosporine dose adjustments, switched back to ATVr/RAL |
| 7 | F | 55 | 2015 | Tacrolimus | DRVr//RAL | DRVc/DTG | Increment of serum creatinine (+ 23%), nausea and vomiting, switched back to DRVr//RAL |
| 8 | M | 57 | 2015 | Cyclosporine | TDF/FTC/DTG | TAF/FTC/DTG | DTG-based HAART maintained |
| 9 | M | 55 | 2016 | Cyclosporine | TDF/FTC/RAL | TAF/FTC/DTG | Increment of serum creatinine (+ 125%), variable cyclosporine concentrations, switched to TAF/FTC/RAL |
| 10 | M | 55 | 2016 | Tacrolimus | TDF/FTC/RAL | TAF/FTC/DTG | Increment of serum creatinine (+ 55%), switched to TAF/FTC/RAL |
3TC lamivudine, ABC abacavir, ART antiretroviral therapy, ATV atazanavir, c cobicistat, DRV darunavir, DTG dolutegravir, F female, FPV fosamprenavir, FTC emtricitabine, HAART highly active ART, M male, r ritonavir, RAL raltegravir, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate, Tx transplantation, u unboosted